

**THOMAS PAUL MATHERS**  
204 Ocean Avenue  
Marblehead, Massachusetts 01945 U.S.A.

**EMPLOYMENT:**

2019-Present

**Allievex Corporation, Marblehead, MA**  
*Founder, President and Chief Executive Officer, Director*

Full profit and loss responsibility for a clinical stage biotechnology company developing novel therapies for the treatment of rare pediatric neurodegenerative diseases. Responsible for all aspects of general management, formulation of current and long-term plans and objectives, administration, finance, and research and development management.

- Company formation and in-license of initial asset base to include tralesenidase alfa, an investigational enzyme replacement therapy for the treatment of children with Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB).
- Completed Series A Preferred private equity financing - \$57MM (2019-2021)
- Completed debt financing of \$5MM (2021)
- Completed convertible debt financing of \$1MM (2018)
- Conducted multiple Type C meetings with FDA and Scientific Advice with EMA
- Conducted multiple clinical studies with ongoing pivotal phase 2/3 trial
- *Private Investor Syndicate: Pappas Capital, Novo Ventures, Asahi Kasei Pharma, LifeSci Ventures, LG Ventures*

2018-Present

**Pappas Capital LLC. Marblehead, MA and Durham, NC**  
*Partner, Pappas Ventures V*

Responsible for new company formation, as well as sourcing and evaluating prospective investment opportunities, and providing expertise and oversight to Pappas portfolio companies. Pappas Capital invests exclusively in the life science sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada.

- As of 12/30/21: 2.6x MOIC; 65% IRR; 75% DPI

2011-2017

**CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) Cambridge, MA**  
*President and Chief Executive Officer, Director*

Full profit and loss responsibility for a publicly traded clinical stage pharmaceutical company focused on the development of a new chemical entity and novel mechanism of action for the acute treatment of episodic migraine.

- Completed \$960 M acquisition by Eli Lilly & Co. (NYSE: LLY)
- Completed follow-on public offering with gross proceeds of \$74.8MM (2016)
- Completed initial public offering with gross proceeds of \$55MM (2015)
- Completed private equity financing totaling \$37.1MM (2015)
- Completed convertible debt financings totaling \$9.5MM (2011)
- Conducted multiple Type A, Type B and Type C meetings with the FDA and negotiated two Special Protocol Assessment - Agreement
- Completed eight clinical studies with pivotal phase 3 trials SAMURAI (2,225 patients), SPARTAN (2,968 patients) and GLADIATOR (2,580 patients)
- Filed two Investigational New Drug Applications 103,420 and 128,230
- *Private Investor Syndicate: Pappas, Domain, Care Capital, TVM, Novo Ventures*

2003-2011

**Peptimmune, Inc.** Cambridge, MA  
*President and Chief Executive Officer, Director*

Full profit and loss responsibility for a privately held clinical stage biotechnology company focused on developing peptides and amino acid copolymers for the treatment of CNS and chronic inflammatory diseases.

- Completed three private equity financings totaling \$84MM (2003, 2005, 2009)
- Completed venture debt financing of \$12MM (2006)
- Negotiated and consummated Option Agreement with Novartis Pharmaceuticals for the acquisition of Peptimmune for \$680MM following completion of successful phase 2 clinical development of lead compound PI-2301 (2009)
- Filed three Investigational New Drug applications (10,992; 61,262; 70,129)
- Strategic sale of PI-2301 phase 2 program to Merck-Serono (2011)
- Strategic sale of all other assets to Zermatt Pharmaceuticals (2011)
- *Private Investor syndicate: NEA, MPM Capital, Prism, Hunt Bioventures, Vanguard*

2002-2003

**Cell Based Delivery, Inc.** Providence, RI  
*President and Chief Executive Officer, Director*

Full profit and loss responsibility for a privately held biotechnology company spin-out from Brown University focusing on the development of ex-vivo gene therapy for treatment of hemophilia.

- Completed Series A private equity financing - \$12MM (2002)
- Oversaw grants from NIST (ATP), DARPA and NIA
- Upon failure of platform technology and lead product candidate, promptly notified Board of Directors and investors and returned Series A investment to investors
- *Private Investor syndicate: TVM, Forbion, Vertical Group, Piper Jaffray*

2001-2002

**Cardion Pharmaceuticals, Inc.** Boston, MA  
**Cardion AG**, Düsseldorf, Germany  
*General Manager and Corporate Vice President*

Establishment and full profit and loss responsibility for a privately held biotechnology company focused on discovery and development of protein therapeutics for the treatment of autoimmune disorders, inflammatory diseases, and cardiovascular diseases, functioning as a subsidiary of a German private biotechnology company.

- Member of senior management team that successfully negotiated acquisition of Cardion by Roche (2002)
- Member of senior management team that completed private equity financing of €11MM (2002)
- *Private Investor syndicate: TVM, Muenchmeyer Holdings, Alpinvest, West LB*

1992-2001

**Genzyme Corporation**, Cambridge, MA  
*Vice President, Strategic Development*

Responsibilities included managing cardiovascular biotherapeutics research and development and all facets of strategic business development for the cardiovascular business unit. Program management of cardiovascular gene therapy, cardiovascular cell therapies and cardiovascular biomaterials. Managed team of principal scientists, medical doctors, program managers, and business development managers. Prior roles: *Senior Director, Cardiovascular Global Marketing; Northeast Regional Sales Manager*

1991-1992

**Pfizer, Incorporated**, Virginia Beach, VA  
*Professional Sales Representative*

**MILITARY  
EXPERIENCE:**

1988-1991      **Captain, United States Army - Aviation, Savannah, GA**  
*Apache Attack Helicopter Pilot and Platoon Leader*

Awarded Air Medal, two Army Commendation Medals, Army Achievement Medal for actions in the 1991 Gulf War. Planned and led highly successful combat multi-helicopter operations against Iraqi Republican Guard forces during Operation Desert Storm

**EDUCATION:**

**United States Military Academy, West Point, NY**  
Bachelor of Science, Engineering (1988)  
Dean's List, Superintendent's Award, three Varsity Football Letters

**BOARDS:**

*Current:* Allievex Corporation; Biotechnology Industry Organization (BIO), Department of Veteran's Affairs Research Advisory Committee of Gulf War Veteran's Illnesses

*Prior:* LifeSci Acquisition Corp. (NASDAQ: LSAQ); 4D Molecular Therapeutics (NASDAQ: FDMT); Board of Trustees, Butler University; CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD); BIO [2008 – 2017] – Chairman, Intellectual Property Subcommittee; CureFAKtor, LLC; Déclion Holdings; Peptimmune, Inc.; Cell Based Delivery, Inc.; Chairman, Parish Finance Committee, St. Rose of Lima Church

*Advisory:* Progeria Research Foundation, DADA2 Foundation

*Elected:* Masconomet Regional School System 2013 - 2016

**PATENTS:**

US 6,610,071 "Suture System for Cardiac Valvuloplasty"  
US 8,546,532 "Design and Synthesis of Directed Sequence Polymer Compositions and Antibodies Thereof for the Treatment of Protein Conformational Disorders"  
US 9,533,037 "Methods for Designing and Preparing Vaccines Comprising Directed Sequence Polymer Compositions via the Directed Expansion of Epitopes"

**ADDITIONAL:**

Married (31 years), two children and avid sports enthusiast.  
Basic German and French language skills. Licensed commercial rotary wing pilot